根据CVS Health发布的官方声明，自2026年10月1日起，Zepbound将重新作为优选药物被纳入其最常见的商业处方集。此前，CVS Caremark曾于2024年底将Zepbound剔除，转而优先覆盖诺和诺德（Novo Nordisk）的Wegovy，以期获得更有利的定价。与此同时，自2026年6月1日起，CVS ...

CVS Caremark will resume covering the weight loss drug Zepbound this year after it removed it from its list of covered ...

WOONSOCKET, R.I., Oct. 13, 2011 /PRNewswire via COMTEX/ -- CVS Caremark (NYSE: CVS) announced today the release of the Caremark.com Droid application. Available at no cost at the Android Market, this ...

Rising prescription drug costs remain a top healthcare concern, with pharmacy benefit managers (PBMs) facing heightened scrutiny for their role in managing prescription drug benefits for insurers and ...

In a reversal from last year, CVS will begin covering Eli Lilly's Zepbound and Foundayo in its standard prescription plan, a ...

As part of updates to its standard formulary, CVS Caremark has removed Amjevita and now prefers Hyrimoz and an unbranded biosimilar. Beginning in January 2024, CVS Caremark will implement many changes ...